EAST BRUNSWICK, N.J., June 9, 2008 (PRIME NEWSWIRE) -- Savient Pharmaceuticals, Inc. (Nasdaq:SVNT) today announced that President and CEO Christopher G. Clement is a finalist for The New Jersey Ernst & Young Entrepreneur Of The Year(r) 2008 Awards. According to Ernst & Young LLP, the awards program recognizes entrepreneurs who demonstrate extraordinary success in the areas of innovation, financial performance and personal commitment to their businesses and communities. Christopher Clement was selected as a finalist from over 50 nominations by a panel of independent judges. Award winners will be announced at a special gala event on Thursday, June 19th, 2008 at the Marriott Teaneck at Glenpointe, Teaneck, New Jersey.
"I am honored to be recognized by Ernst & Young and share this with everyone on the Savient team," stated Christopher Clement, President and CEO. "We have worked together as a team to achieve the success that we have made during these past years. To be acknowledged by Ernst &Young validates the hard work and accomplishments that all of us at Savient have achieved."
The Ernst & Young Entrepreneur Of The Year awards program celebrates its 22nd anniversary this year. The program has expanded to recognize business leaders in over 135 cities in 50 countries throughout the world.
Regional award winners are eligible for consideration for The Ernst & Young Entrepreneur Of The Year national program. Award winners in several national categories, as well as the overall national Ernst & Young Entrepreneur Of The Year award winner, will be announced at the annual awards gala in Palm Springs, California on November 15, 2008. The awards are the concluding portion of Ernst & Young's Strategic Growth Forum, the nation's most prestigious gathering of high-growth, market-leading companies.
Sponsors
Founded and produced by Ernst & Young LLP, The Entrepreneur Of The Year awards are pleased to have SAP and the Ewing Marion Kauffman Foundation as national sponsors.
The New Jersey Program is also sponsored locally by the following:
Platinum Level Marsh Gold Level Bowne, Curran & Connors and Scherzer International Silver Level Gibbons P.C, NJBIZ and Withum Smith + Brown
For more information please contact Mary Coleman, Director Investor Relations at Savient Pharmaceuticals, Inc.
About Savient Pharmaceuticals, Inc.
Savient Pharmaceuticals is a biopharmaceutical company engaged in developing and distributing pharmaceutical products that target unmet medical needs in both niche and broader markets. The company's product development candidate, Puricase(r) (pegloticase) for treatment-failure gout, has reported positive Phase 1, 2 and 3 clinical data. Patient dosing in the Phase 3 clinical studies began in June 2006; patient enrollment was completed in March 2007; and the Phase 3 clinical studies were completed in October 2007. Savient has exclusively licensed worldwide rights to the technology related to Puricase from Duke University and Mountain View Pharmaceuticals, Inc. Savient's experienced management team is committed to advancing its pipeline and expanding its product portfolio by in-licensing late-stage compounds and exploring co-promotion and co-development opportunities that fit the Company's expertise in specialty pharmaceuticals and biopharmaceuticals with an initial focus in rheumatology. Savient also manufactures and supplies Oxandrin(r) (oxandrolone tablets, USP) CIII in the U.S. Puricase is a registered trademark of Mountain View Pharmaceuticals, Inc. Further information on Savient can be accessed by visiting: http://www.savient.com.
About Ernst & Young's Entrepreneur Of The Year
Ernst & Young's Entrepreneur Of The Year is the world's most prestigious business award for entrepreneurs. The award makes a difference through the unique way it encourages entrepreneurial activity among those with potential and recognizes the contribution of people who inspire others with their vision, leadership and achievement. As the first and only truly global award of its kind, Ernst & Young Entrepreneur Of The Year celebrates those who are building and leading successful, growing and dynamic businesses, recognizing them through regional, national and global awards programs in more than 135 cities in 50 countries.
About Ernst & Young
Ernst & Young is a global leader in assurance, tax, transaction and advisory services. Worldwide, Ernst & Young's 130,000 people are united by their shared values and an unwavering commitment to quality. Ernst & Young makes a difference by helping its people, clients and wider communities achieve potential.
For more information, please visit www.ey.com.
Ernst & Young refers to the global organization of member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients.
SVNT-G